Play Earnings CallPlay Earnings Call
Jazz Pharmaceuticals plc (JAZZ) TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA May 27, 2026 2:00 PM EDT
Company Participants
Robert Iannone – Executive VP, Chief Medical Officer and Global Head of Research & Development
John Bluth – Head of Investor Relations
Conference Call Participants
Joseph Thome – TD Cowen, Research Division
Presentation
Joseph Thome
TD Cowen, Research Division
Hi, everyone. Good afternoon again, and thank you for joining us at the 2026 TD Cowen Biotech Oncology Innovation Summit. I’m Joe Thome, one of the biotech analysts here on the team at TD Cowen. It’s my pleasure to have with me today 2 members of the Jazz Pharmaceuticals team. We have EVP Global Head of R&D and CMO, Rob Iannone. And we have the Head of Investor Relations, John Bluth. So thanks, guys, for joining us today. Maybe to kick things off…
Robert Iannone
Executive VP, Chief Medical Officer and Global Head of Research & Development
Nice to see you, Joe.
Joseph Thome
TD Cowen, Research Division
Nice to see you here, both.
John Bluth
Head of Investor Relations
And Joe, just very quickly, a little housekeeping. Rob and I may make some forward-looking statements today. So please do refer to our SEC filings to reference those. We also may refer to earnings and guidance. If we do, we’re referring to our most recent guidance as of our first quarter update, and the same is true of any non-GAAP financial measures we discuss. You’ll find a reconciliation in our first quarter earnings report. Thanks, Joe, and happy to be here with you.
Joseph Thome
TD Cowen, Research Division
Yes. Maybe just to start things off, obviously, a lot of progress at Jazz over the past year. Maybe kind of if you want to give us a brief update on kind
